课题基金 / 基金详情

Technical feasibility study for the detection of target biomarkers in menstrual blood for the diagnosis of polycystic ovary syndrome.

Technical feasibility study for the detection of target biomarkers in menstrual blood for the diagnosis of polycystic ovary syndrome.
检测经血中目标生物标志物诊断多囊卵巢综合征的技术可行性研究。
批准号:
10100544
负责人:
金额:
$22.65万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Woost is s a new fem-tech start-up who are dedicated to the development of novel technologies to significantly improve the awareness and diagnosis of gynaecological health conditions starting with polycystic ovary syndrome (PCOS),an ovarian dysfunction. We are devoted to building a community,in which women's health concerns are effectively targeted and more importantly,being heard.In the current healthcare ecosystem women experiencing any symptoms have to overcome restrictions on availability and accessibility and travel to the doctor's office to receive medical help.After attending their appointments,4 in 5 women felt they were not properly listened to by healthcare professionals leading to disheartening experiences women have been through from their long journey to diagnosis.PCOS has a direct relation to the emergence of life-threatening diseases (e.g.diabetes) and thus an earlier diagnosis is tremendously important for women's quality of life.And yet, the pandemic further limited the accessibility to healthcare and enhanced concerns around the resulting delayed diagnoses for these women.Woost's mission is to eliminate these restrictions and provide women the support they need to take control of their own health journey.We put women at the centre of their healthcare needs by directly offering them diagnostic tools to understand the basis of their symptoms.Women can join our digital platform and order our at-home test kits to examine menstrual blood for an earlier diagnosis of PCOS.Having access to their results from the comfort of their home eliminates any previously experienced location- and time-specific constraints and facilitates an earlier and more detailed diagnosis of gynaecological conditions. Providing remote triage, we are removing the need for clinicians to perform routine analytical testing and thus we are increasing the time clinicians can now spend on patient engagement and disease treatment.Woost's menstrual blood tests will be easy-to-use,affordable and accessible to be used by any woman anywhere to monitor their gynaecological well-being
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金